OptiNose (OPTN NASDAQ) stock market data APIs
$9.5677
0.06(0.6%)
as of May 20, 2025
Try our APIs with
free plan!
OptiNose Financial Data Overview
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc.
Prev. Close
9.5677
Open
9.6321
High
9.7887
Low
9.552
52 wk Range
4.815-19.5
Market Cap
97 223 K
Shares Outstanding
10 127 K
Revenue
81 856 K
EPS
-1.92
Beta
-0.885
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get OptiNose data using free add-ons & libraries
Get OptiNose Fundamental Data
OptiNose Fundamental data includes:
- Net Revenue: 81 856 K
- EBITDA: -15 570 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OptiNose News
New
Paratek expands commercial portfolio with Optinose
Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product offerings. The companies signed a definitive merger agreement in March 202...
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialist...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or br...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, OPTN, AZEK, MESA on Behalf of Shareholders
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or br...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
